Flavone Acetic Acid (FAA) is a synthetic flavonoid compound with potent activity against a variety of transplantable murine tumours including many which are resistant to conventional cytotoxic drugs (Corbett et al., 1986; Bibby et al., 1988a) . FAA possesses several features unusual for an anticancer agent. Thus FAA's activity appears to be confined to tumours growing subcutaneously (s.c.) as solid lesions; its effect on tumour cells in culture or against leukaemia models being minimal (Bibby et al., 1987; Finlay et al., 1988; . These characteristics, coupled with a toxicity profile unlike that of most antineoplastic drugs (Zaharko et al., 1986) , suggest that the drug may have an indirect mode of action.
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A possible way whereby FAA might exert its antineoplastic effects is via interruption of the tumour blood supply. A number of authors, using techniques as varied as magnetic resonance spectroscopy, dye perfusion and pointcounting of vascular channels, have shown that FAA administration rapidly effects a dramatic reduction in tumour blood flow (Evelhoch et al., 1988; Bibby et al., 1989a; Zwi et al., 1989) . Most recently, by means of a radioactive-tracer clearance assay, we have confirmed this inhibition of tumour blood flow by FAA and provided evidence that tumour necrosis factor cz (TNFx) is responsible for this effect (Mahadevan et al., 1990) .
For a given tumour, FAA appears to be less effective against early stage disease than against its more advanced, better established counterpart (Bibby et al., 1988b) . Certainly the studies on blood flow inhibition cited above were conducted on overt, palpable tumours which possess a functional microvasculature (Folkman & Cotran, 1976) . We are unaware of any studies on the effects of FAA on the early development of tumour microcirculation. Accordingly the present study, using the clearance of locally-injected '33Xe as an indication of blood flow (Mahadevan et al., 1989 (Mahadevan et al., , 1990 , was undertaken to examine the possible effects of FAA on this early stage of neoplastic growth. Protamine, an argininerich basic protein which is capable of inhibiting tumour neovascularisation (Folkman, 1985; Taylor & Folkman, 1982) , was used as a positive control. We show here that the inhibition of tumour blood flow achieved by FAA administration depends on an established tumour microvasculature with no evidence that the drug inhibits new vessel formation. days post sponge implantation gave a 100% tumour take. The tumours were palpable between 12 and 14 days following cell injection.
Bloodflow measurement Blood flow measurement was performed as described previously (Mahadevan et al., 1989 (Mahadevan et al., , 1990 . Ten fl of '33Xe solution in physiologic saline were injected into the centre of the implanted sponge and the washout of radioactivity was monitored at intervals of 1 min for 10 min. Clearance of '33Xe from implanted sponges was measured on days 4, 6, 11 and 15 post-tumour cell injection.
Protamine or FAA treatment
To monitor the effects of protamine and FAA on the development of tumour vascularisation sponges were implanted into 15 animals. Three days after sponge implantation each animal was injected with 1 x 106 Colon 26 cells in 100 gil of PBS into the centre of the sponge and the mice were assigned arbitrarily to three groups (n = 5 per group).
On the next four successive days animals in Group 1 received i.p. injection of FAA, 150 mg kg-' day-'; animals in Group 2 received i.p. injections of protamine, 50 mg kg-' day-'
and control animals in Group 3 received i.p. injections of similar volumes of saline diluent. Blood flow was measured 3, 6 and 10 days after completion of drug treatment. The effect of FAA on blood flow of established tumours was assessed by implanting sponges into 20 animals and establishing tumours as detailed above. Fourteen days after cell injection, when all animals had palpable tumours, ten animals received a single i.p. injection i.p. of FAA (200 mg kg-') while ten animals were injected i.p. with a similar volume of saline diluent. Blood flow was assessed on days 1 and 2 post-di ig injection.
Measurement of tumour volume Calipers were used to measure the tumours in two dimensions and volumes were calculated from the formula a x b a where 'a' and 'b' are the minor and major dimensions respectively (Bibby et al., 1988a ).
Blood flow in non tumour-bearing sponges after FAA administration Fifteen animals received sponge implants. Twenty eight days later animals in Group 1 (n = 5) received a single i.p. injection of FAA at 200 mg kg-', animals in Group 2 (n = 5) received a single i.p. injection of FAA at 250 mg kg' and animals in Group 3 (n = 5) were injected with saline diluent. Blood flow measurements were recorded 4 h post drug injection.
Statistical evaluation
All statistical comparisons were made using Student's t-test.
Results
Effect of tumour development on bloodflow The effects of tumour growth on '33Xe clearance are illustrated in Figure 1 . Developing tumour, whether initiated by the injection of 1 x 105 or 1 x 106 cells, caused a significant reduction in mean T1 such that 7 days after sponge implantation (4 days after cell injection) the T1 was 14-15 min compared with 27 min in the control sponges, while on day 14 post-sponge implantation the respective values were 8 min and 21min (P<0.01).
Effect of FAA and Protamine Treatment Figure 2 depicts the effect of FAA on tumour blood flow depending on whether it was delivered 'early' or 'late' in tumour development. Four consecutive daily injections of FAA initiated 1 day after the implantation of the neoplastic cells had no significant effect on '33Xe clearance times from the developing tumour when compared to saline treated controls (e.g. Tt at 10 days post sponge implantation was 16 min for FAA vs 14 min for saline-treated sponges). By comparison a single injection of FAA on day 17 after sponge implantation, and 14 days after tumour cell injection, resulted 1 day later in a highly significant (P .0.001) prolongation of T1 from 7 min for control animals to 47 min for FAA treated animals ( Figure 2) .
In contrast to the lack of effect manifested by multiple injections of FAA early in tumour growth Protamine given at the same points in time caused a signficant extension of T1 times. Thus on days 10 and 13 post-sponge implantation protamine-treated animals showed mean T1 values of 27.5 ± 5.3 min and 22.8 ± 2.7 min which differed significantly 
Discussion
We previously have used the '33Xe clearance technique as the basis for developing a dynamic assessment of blood flow (Mahadevan et al., 1989) and have shown, using this assay, that FAA acts to shut down tumour vascularity via the effects of TNFx (Mahadevan et al., 1990) .
Using this technique we now show that the effect of FAA is dependent on an established microvasculature within the (Figure 2 ) nor did it retard tumour growth (Table I) . In contrast to these results protamine, which has been shown to be capable of inhibiting the angiogenic response and thereby limiting tumour growth (Taylor & Folkman, 1982; Folkman, 1985) , brought about significant inhibition of tumour blood flow development, and retarded tumour growth (Figure 2 , Table I ). By 18 days post sponge implantation, at a time when full vascularisation of the sponge/tumour had been achieved (Figure 1 ), a single dose of FAA produced a highly significant reduction in '33Xe clearance compared with controls (Figure 2 ). This inhibition of blood flow was persistent even up to 10 days after drug administration (data not shown). In our previous report we showed that these reductions in vascular flow were associated with a drastic limitation in the size of the treated tumours (Mahadevan et al., 1990) .
It seems clear from these experiments that the efficacy of FAA in acting against a sensitive tumour is dependent upon there already being an established microvasculature. Certainly this could account for the observations that FAA is more effective against late stage disease (Bibby et al., 1988b) and help to explain the variation in response to FAA shown by tumours in distinct anatomical locations (Bibby et al., 1989b; Finlay et al., 1988) . Interestingly the age, or the development, of the microvasculature per se is not the sole determinant in regulating FAA activity. Thus when fully vascularised sponges, showing similar T1 values to those observed in established tumours, were utilised FAA had no effect on blood flow. Since the effects of FAA are mediated, in part at least, via the cytokine TNFa (Smith et al., 1987; Mace et al., 1990; Mahadevan et al., 1990) it may be that differences in either the production of or the response to, this molecule underlie the divergent response.
The major source of TNFx is the macrophage (Le & Vilcek, 1987) . TNFa is a plurifunctional protein with important biological effects on a variety of target cell types, including the vascular endothelium (Le & Vilcek, 1987) . TNFx induces endothelial cells to elaborate a tissue factor-like procoagulant, and to suppress an essential anti-coagulant cofactor synthesised by endothelial cells (Fajardo, 1989) , thereby causing intravascular thrombosis (Fajardo, 1989) . Thrombotic occlusion of the vascular bed is believed to be the mechanism underlying TNFa-induced haemorrhagic necrosis of tumours (Smith et al., 1987; Nawroth et al., 1988) . In support of this hypothesis, Nawroth et al. (1988) showed that tumour-bearing mice anticoagulated with coumarin, exhibited significantly less tumour necrosis in response to TNFa when compared with non-anticoagulated control animals. It has been shown that some tumours may be composed of a large percentage of macrophages, up to 65% for example (Russell et al., 1980) . The granulation tissue occupying the implanted sponge may not possess the same large macrophage content as is present in the Colon 26 tumour. Accordingly, the divergent responses to FAA seen between tumour-bearing and non tumour-bearing sponges (Figure 2 , Table II ) may reflect variation in levels of local TNFa production as a consequence of cellular composition. Alternatively, it may be that levels of TNFx production are comparable, but that the responses of tumour vessels and normal vessels are different. In this context, it is interesting to note that Nawroth et al. (1988) found that the vascular bed in a murine fibrosarcoma, but not adjacent normal microvasculature, was susceptible to the thrombogenic effect of systemically-administered TNFa. These authors showed also that a soluble factor derived from the fibrosarcoma cells in culture, and devoid of intrinsic procoagulant activity, potentiated significantly the induction of endothelial tissue factor by TNFa (Nawroth et al., 1988) . Recently Murray et al. (1989) observed that FAA activated the process of coagulation both in tumour-bearing and non-tumour-bearing mice. However, the intensity of this effect was greater in the tumour-bearing animals. Furthermore, the transient nature of the coagulopathy in non-tumour bearing animals contrasted sharply with the prolonged effects on coagulation in animals with tumours (Murray et al., 1989) .
Whatever the basis of the observed response it is clear from our studies that FAA does not inhibit the development of tumour blood vessels but acts against established tumour, but not normal, microvasculature.
